Skip to main content
MXCT
NASDAQ Industrial Applications And Services

MaxCyte to Pay $151.8M for Akron Bio: $105M Cash, 20.6M Shares, $20M Deferred

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Medical Device Stocks · Healthcare
Sentiment info
Positive
Importance info
9
Price
$1.36
Mkt Cap
$134.168M
52W Low
$0.643
52W High
$1.805
52W Position info
111% above low
Off High info
25% below high
Rel. Volume info
1.7× avg
Market data snapshot near publication time

MXCT has more than doubled off its 52-week low of $0.643.

Summary

MaxCyte agreed to acquire Akron Bio for $151.8 million — $105.0 million cash, 20.6 million shares and $20.0 million of deferred payments — a deal expected to nearly double revenue and accelerate profitability, funded partly by a new $75.0 million MidCap credit facility.


Key Events · M&A and Partnerships · MXCT

  • Akron Bio Acquired for $151.8M

    MaxCyte will pay $105.0 million cash at closing, issue 20,639,733 shares (~$26.8 million at the November 9 close) and pay $20.0 million in guaranteed deferred cash, $10.0 million each in January 2028 and January 2029.

  • Dilution and Cash Impact

    The 20,639,733-share stock consideration equals about 20% of the 103,250,292 shares outstanding as of November 9, 2026. Cash and investments are guided to roughly $40-45 million at year-end 2026 after the $105.0 million cash payment and deal expenses.

  • New $75M MidCap Facility

    A $55.0 million term loan plus $20.0 million revolver; MaxCyte expects to draw $20.0 million of the term loan and $2.0 million of the revolver at closing to help fund operations through profitability.

  • Closing Conditions and Lock-Up

    Closing is expected before year-end 2026, subject to HSR clearance and Nasdaq listing approval of the shares — no financing condition and no stockholder vote. Sellers are locked up for six months and get registration rights.


Analysis · MXCT · Industrial Applications And Services

MaxCyte is buying Akron BioProducts from Arcline for $151.8 million — $105.0 million cash at closing, 20,639,733 shares worth roughly $26.8 million at the November 9 close, and $20.0 million of guaranteed deferred cash in 2028 and 2029. Akron is expected to add about $28 million of 2026 revenue and $7-8 million of EBITDA, nearly doubling MaxCyte's revenue base and pulling forward profitability. The cost is real: the share issuance is dilutive, cash drops to roughly $40-45 million at closing, and the company takes on a new MidCap facility of up to $75.0 million with $22.0 million drawn at close. The deal needs HSR clearance and Nasdaq listing approval but no shareholder vote and no financing condition, with closing targeted before year-end 2026.

How filings like this one have moved

In the 30 days to Nov 10, 2026, 52.5% of the 204 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.68%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, MXCT was trading at $1.36 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $134.2M. The 52-week trading range was $0.64 to $1.81. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

MXCT - Latest Insights

MXCT
Nov 10, 2026, 6:01 AM EST
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $1.43
Real-time Price: $1.35 info
Change: -$0.080 (-6%) info
Market Cap: $134.168M info
MXCT
Nov 10, 2026, 6:00 AM EST
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $1.23
Real-time Price: $1.35 info
Change: +$0.1196 (+10%) info
Market Cap: $134.168M info
MXCT
Oct 14, 2026, 8:05 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $1.00
Real-time Price: $1.35 info
Change: +$0.350 (+35%) info
Market Cap: $134.168M info
MXCT
Aug 04, 2026, 8:42 AM EDT
Filing Type: SCHEDULE 13D
Importance Score:
7
Price at Filing: $1.06
Real-time Price: $1.35 info
Change: +$0.290 (+27%) info
Market Cap: $134.168M info
MXCT
Jul 21, 2026, 8:05 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $1.21
Real-time Price: $1.35 info
Change: +$0.1356 (+11%) info
Market Cap: $134.168M info